Skip to main content
SpringerLink
Log in

Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report

  • Day-to-Day Practice
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive cancer. For patients who are diagnosed with advanced stage disease that are not surgical candidates, the disease is universally lethal. Advance has been made to extend survival with molecular target therapy, but durable complete responses are extremely rare. We report an unusual case where a 74-year-old patient with unresectable HCC received eight months of reduced-dose of sorafenib, a tyrosine kinase inhibitor, and achieved a durable complete remission. At the most recent follow up, he remains in remission 16 months after cessation of treatment, without clinical or imaging evidence of disease recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533–543

    Article  CAS  PubMed  Google Scholar 

  2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

    Article  CAS  PubMed  Google Scholar 

  3. So BJ, Bekaii-Saab T, Bloomston MA, Patel T (2008) Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. J Hematol Oncol 1:18

    Article  PubMed  Google Scholar 

  4. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34(4):570–575

    Article  CAS  PubMed  Google Scholar 

  5. Oquiñena S, Iñarrairaegui M, Vila JJ, Alegre F, Zozaya JM, Sangro B (2009) Spontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature. Dig Dis Sci 54(5):1147–1153

    Article  PubMed  Google Scholar 

  6. Yoshida T, Hisamoto T, Akiba J et al (2006) Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25:6056–6066

    Article  CAS  PubMed  Google Scholar 

  7. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3:19

    Article  PubMed  Google Scholar 

  8. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP (2007) Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 6:1932–1941

    Article  CAS  PubMed  Google Scholar 

  9. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:1835–1845

    Article  PubMed  Google Scholar 

  10. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24):11851–11858

    Article  CAS  PubMed  Google Scholar 

  11. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34

    Article  CAS  PubMed  Google Scholar 

  12. Houben R, Voigt H, Noelke C, Hofmeister V, Becker JC, Schrama D (2009) MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol Cancer Ther 8(2):433–440

    Article  CAS  PubMed  Google Scholar 

  13. Huitzel-Melendez FD, Saltz LB, Song J et al (2007) Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients with hepatitis C (C+) versus B (B+) treated with sorafenib (abstract). Data presented at the 2007 ASCO Gastrointestinal Cancers Symposium, January 19–21, 2007, Orlando, FL: (abstract 173)

  14. Bolondi L, Caspary W, Bennouna J et al (2008) Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial (abstract). Data presented at the 2008 ASCO Gastrointestinal Cancers Symposium, January 25–27, 2008, Orlando, FL (abstract 129)

  15. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

No funds were received in support of this study.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Sean Xiang Wang, John R. Pancoast & Olivier Rixe

  2. Department of Veterans Affairs Medical Center, Cincinnati, OH, USA

    Sean Xiang Wang & John R. Pancoast

  3. Southeastern Kentucky Cancer Center, Corbin, KY, USA

    Abigail Byrnes

  4. Department of Radiology, Section of Abdominal Imaging, University of Cincinnati Medical Center, Cincinnati, OH, USA

    Sadhna Verma

  5. Division of Hematology/Oncology, University of Cincinnati, Cincinnati, OH, USA

    Sean Xiang Wang

  6. Department of VAMC, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Sean Xiang Wang

  7. Department of Veterans Affairs Med. Center, Hematology/Oncology Section, 3200 Vine Street, B234f, mc 111-D, Cincinnati, OH, 45220, USA

    Sean Xiang Wang

Authors
  1. Sean Xiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abigail Byrnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sadhna Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John R. Pancoast
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivier Rixe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean Xiang Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, S.X., Byrnes, A., Verma, S. et al. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Targ Oncol 5, 59–63 (2010). https://doi.org/10.1007/s11523-010-0133-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-010-0133-x

Keywords

Search

Navigation